December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

33.70 -0.53 (-1.55%)
Streaming Delayed Price Updated: 3:11 PM EDT, Apr 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone. ↗
Analysts say Alkermes' drug is clearly active. But investors have concerns. 
Via Investor's Business Daily
News headline image
Why NASDAQ:ALKS Is a Promising High-Growth Stock in the Midst of Consolidation. ↗
ALKERMES PLC (NASDAQ:ALKS), a strong growth stock, setting up for a breakout. 
Via Chartmill
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗
 
Via Benzinga
News headline image
Alkermes Honors Women's Equality Day
Via ACCESSWIRE
News headline image
While growth is established for NASDAQ:ALKS, the stock's valuation remains reasonable. ↗
Looking for growth without the hefty price tag? Consider ALKERMES PLC (NASDAQ:ALKS). 
Via Chartmill
News headline image
NASDAQ:ALKS is showing good growth, while it is not too expensive. ↗
Despite its growth, ALKERMES PLC (NASDAQ:ALKS) remains within the realm of affordability. 
Via Chartmill
News headline image
Hovnanian Enterprises, LexinFintech Holdings And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded mixed, with the Dow Jones falling around 10 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
3 Top Biotech Stocks Defying the Bear Market ↗
Biotech is still booming, if you pick the right biotech stocks. 
Via The Motley Fool
News headline image
Earnings Preview: Alkermes ↗
 
Via Benzinga
News headline image
Where Alkermes Stands With Analysts ↗
 
Via Benzinga
News headline image
Alkermes Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
Analyst Expectations for Alkermes's Future ↗
 
Via Benzinga
News headline image
Alkermes Clocks Over 100% Jump In Q2 Sales and Profits On Reinstated Product Royalty From Long-Acting Invega ↗
Alkermes plc (NASDAQ: ALKS) reported Q2 adjusted EPS of $0.55 compared to $0.06 a year ago, missing the consensus of $0.56 
Via Benzinga
News headline image
Sarissa Capital Urges Alkermes Shareholders to Vote “FOR” Sarah Schlesinger and “WITHHOLD” Incumbent Director Richard Gaynor
From Sarissa Capital Management LP
Via Business Wire
News headline image
Sarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders
From Sarissa Capital Management LP
Via Business Wire
News headline image
Independent Proxy Advisory Firm ISS Agrees With Sarissa Capital That Shareholders’ Interests Would Be Best Served With Direct Shareholder Representation on the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
The Latest Analyst Ratings for Alkermes ↗
 
Via Benzinga
News headline image
A Preview Of Alkermes's Earnings ↗
 
Via Benzinga
News headline image
Independent Proxy Advisory Firm ISS Concludes That Sarissa Capital Has Made a Compelling Case for Change to the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Sarissa Issues Presentation Highlighting the Need for Shareholder Representation on the Alkermes Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Sarissa Urges Shareholders to Vote for Sarissa Nominees to Provide Much Needed Oversight and Accountability to Alkermes
From Sarissa Capital Management LP
Via Business Wire
News headline image
Sarissa Capital Highlights Misleading Claims Made by Alkermes in Its Attempt to Thwart Shareholder Representation on the Board
From Sarissa Capital Management LP
Via Business Wire
News headline image
Alkermes Raises FY23 Outlook Following Arbitration Award from Janssen Agreements ↗
 
Via Benzinga
News headline image
Sarissa Urges Alkermes Shareholders to Vote the Universal Blue Card to Upgrade Alkermes for the Benefit of Shareholders
From Sarissa Capital Management LP
Via Business Wire
News headline image
Alkermes Stock Sees Rising Relative Strength Rating ↗
The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77. 
Via Investor's Business Daily
News headline image
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
News headline image
Alkermes: Commercialization Program On Track, Sales Coming In Strong ↗
The bigger biotechs have done a good job lately, with solid earnings to date. Speaking of which, Alkermes plc has recently exceeded estimates. Let's take a closer look at the company's performance. 
Via Talk Markets
News headline image
Alkermes Stock Sees Rising Relative Price Strength ↗
The Relative Strength (RS) Rating for Alkermes stock entered a new percentile Friday, with an increase from 79 to 86. 
Via Investor's Business Daily
News headline image
Seattle Genetics' 'Refreshing' Enthusiasm Drives Stock Surge; Alkermes Briefly Breaks Out ↗
Seattle Genetics' guidance deliberately excludes a looming opportunity for Padcev. 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.